![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 51, 48451-48457, December 21, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
andFrom the Department of Molecular Biology and Genetics, University of Guelph, Guelph, Ontario N1G 2W1, Canada
Received for publication, April 20, 2001, and in revised form, September 11, 2001
| |
ABSTRACT |
|---|
|
|
|---|
The glycosylation of integrins and other
cell surface receptors is altered in many transformed cells. Notably,
an increase in the number of Integrins and other cell surface receptors are extensively
N-glycosylated by enzymes that reside in the endoplasmic
reticulum (ER)1 and Golgi
complex. Upon the insertion of newly synthesized polypeptides into the
ER, oligosaccharyltransferase adds
Glc3Man9GlcNAc2-P-P-dolichol to
asparagine residues. The three glucoses and all but the last five
mannose residues on the oligosaccharide core are progressively trimmed
off as the protein moves from the ER to the cis-Golgi by a
series of glucosidases and mannosidases. Upon entering the medial
Golgi, the N-acetylglucosaminyltransferases GlcNAc-TI and GlcNAc-TII begin the process of rebuilding the oligossacharides with
GlcNAc residues. In various cells and tissues, GlcNAcs-TIII, -TIV,
and/or -TV make subsequent GlcNAc additions, and this rebuilt backbone
serves as a structure to which other complex sugars are added.
Many cancer cells exhibit altered glycosylation patterns on surface
receptors, but the complexity and differences in oligosaccharides in
normal cells have made it difficult to establish causal relationships between sugar modifications and abnormal cell growth properties. Nevertheless, there is a growing body of convincing evidence that hyperactivity of GlcNAc-TV promotes a metastatic phenotype (1-9). We showed recently that the transmembrane domain of Considering that integrin functions are dependent upon glycosylation
and because all of the molecules of interest including E5, 16K, the
PDGF- Cell Culture, Transfections, Antibodies, and Lectins--
Human
embryonal kidney cells (HEK293) constitutively expressing T7 polymerase
(a gift from Dr. M. A. Billeter, Institut fur Molekularbiologie,
Abteilung, Switzerland) were grown in Assembly of T7-tagged Wild Type and W728G Mutant Cloning of Human 16K cDNA and Generation of 16K
Mutants--
The human 16K cDNA was cloned by reverse
transcription-PCR from the human pancreatic tumor cell line CRL-80
using the primers (H16K-Up) 5'-ACATGTCCGAGTCCACG-3' and (H16K-DN)
5'-CTACTTTGTGGAGAGGATG-3'. The HSV-tagged 16K cDNA was made by
directionally cloning a PCR product into the EcoRI and
BamHI sites of the plasmid XJ40-KKO (36), which adds the HSV
tag to the carboxyl terminus of the protein. The 16K PCR fragment was
generated using the primers (16K3-UP) 5'-CGCGAATTCATGTCCGAGTCCAAGA-3'
and (16K-3DN) 5'-CGGGATCCCTTTGTGGAGAGGATG-3'. 16K mutants were
generated by PCR amplification using primers with appropriate
restriction enzymes spanning amino acids identified in Fig. 4. PCR
fragments were HSV epitope-tagged at the carboxyl terminus by cloning
into pXJ40-KKO.
Assembly of T7-tagged EGF Receptor--
The EGF-R was cloned
into the pXJ41 expression vector, and oligos encoding the 71 amino acid
signal sequence (37) followed by the T7 epitope tag were annealed and
ligated upstream of the coding sequence.
Western Blot Analysis--
RIPA lysates made from HEK293 cells
transiently transfected with pXJ41-T7- Migration/Invasion Assays--
Invasion assays (38) were
performed in Costar transwell chambers in which 10 µg of
bovine plasma fibronectin or laminin (Sigma) was adsorbed overnight.
Before adding the cells, the protein matrix was rehydrated for 2 h
with Adhesion Assays and Immunofluorescence--
HEK293 cells were
transfected with HSV-tagged 16K for 12 h, split, and aliquoted
onto untreated coverslips or coverslips coated with 1.8 µg of
fibronectin or laminin. After an overnight incubation at 37 °C,
cells were fixed in 4% formaldehyde, permeabilized with 0.1% Triton
X-100, blocked in 10% goat serum, and treated with anti-HSV antibody
for 1 h at room temperature. Following three washes in PBS, cells
were incubated in 2% goat serum containing Alexa-488-conjugated rabbit
anti-mouse secondary antibody, washed, mounted, and viewed using a
Zeiss Axiovert 200.
Pulse-Chase Experiments--
HEK293 cells transiently
transfected with Flow Cytometry--
Cells transfected with wild type T7-tagged
Identification of Processing Intermediates of
The previously reported interaction of endogenous 16K and
Expression of 16K Inhibits Inhibition of The Effect of 16K on The Inhibition of Glycosylation by 16K Is Not Dependent upon a
Direct Association with
The interaction of 16K with Amino Acids within the Transmembrane Domain of Glycosylation of the EGF-R Is also Inhibited by 16K--
The
receptor for the EGF-R also has Integrins and other surface receptors undergo extensive
post-translational modification throughout the exocytic pathway with glycosylation being a major determinant of receptor functions. Considering that the acidic environment of this pathway is regulated by
V-ATPase, it is intriguing that one of the subunits of this enzyme,
16K, can play a role in processing. As we have shown, this involvement
appears to be independent of V-ATPase activity, indicating that 16K in
fact has multiple roles. There is little known about the cellular
regulators of glycosylation, and our data show that for GlcNAc-TV, a
specific subdomain of 16K, can have a major impact on There are several events that might explain these data. On one hand,
16K may act as a trafficking molecule to assist in the movement of
For various reasons, the first of these explanations is not
satisfactory. The fact that an Nevertheless, it should be noted that the V0 subunit
of the yeast V-ATPase, which is comprised of a hexamer of 16K, Vma6, Vph1, Vma11, and Vma16, has recently been found to catalyze membrane fusion of vacuoles in a calmodulin/calcium-dependent and
V-ATPase-independent manner (53). The authors propose that
V0 subunits from opposing membranes form a pore
spanning both membranes, providing a mechanism for membrane fusion.
Thus, the possible involvement of 16K in the trafficking of molecules
within compartments should not be excluded.
The possibilities that 16K regulates GlcNAc-TV or that it plays a role
in the identification of glycosylation targets of the transferase must
be considered in light of the fact that 16K is a highly hydrophobic
membrane protein. GlcNAc-TV has a single membrane-spanning hydrophobic
domain compared with the four within a 16K monomer or the twenty-four
within the 16K hexamer that constitutes the proton channel of V-ATPase.
Although there is as yet no supporting evidence, 16K could act as a
docking site in the membrane to cluster molecules with complementing
functions. The transmembrane 4 superfamily family of tetraspan
proteins is believed to carry out such a role in plasma membranes (54,
55). It is relevant in this regard that the transmembrane domain of
The reduction in There are very few reports in the literature of cellular regulators of
GlcNAc transferases. Guo et al. (52) reported a modest (<50%) decrease in GlcNAc-TV activity in response to the
metastasis-suppressor gene nm23-H1 and the tumor suppressor
gene p16, but they did not examine specific receptors such
as
1,6-branched N-linked
oligosaccharides correlates strongly with invasive growth of cells. An
ectopic expression of the Golgi enzyme
N-acetylglucosaminyltransferase V (GlcNAc-TV), which forms
1,6 linkages, promotes metastasis of a number of cell types. It is
shown here that the 16-kDa transmembrane subunit (16K) of vacuolar
H+-ATPase suppresses
1,6 branching of
1
integrin and the epidermal growth factor receptor. Overexpression of
16K inhibits cell adhesion and invasion. 16K contains four hydrophobic
membrane-spanning
-helices, and its ability to influence
glycosylation is localized primarily within the second and fourth
membrane-spanning
-helices. 16K also interacts directly with the
transmembrane domain of
1 integrin, but its effects on
glycosylation were independent of its binding to
1
integrin. These data link cell surface tumor-related glycosylation to a
component of the enzyme responsible for acidification of the exocytic pathway.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 integrin and the epidermal growth factor receptor
(EGF-R) are both targeted by GlcNAc-TV (10-13), which adds GlcNAc to
the oligosaccharide backbone via a
1,6 linkage. In addition, both
receptors can have significant involvement in cancer cells.
1 integrin is implicated in the invasive processes of
many tumor cells (14-19), and an elevated expression of the EGF
receptor is an indicator of poor prognosis for many cancers including
breast, ovarian, and uterine (20-23).
1
integrin interacts with the 16K subunit of vacuolar
H+-ATPase (V-ATPase) (24), the enzyme that acidifies the
Golgi and exocytic and endocytic compartments (25, 26). 16K is a membrane-spanning protein that folds as a four-helix bundle and assembles into a hexamer, forming the membrane proton channel of the
enzyme. In addition to its role in the V-ATPase, 16K has been reported
to form gap junctions and neurotransmitter release channels (27-29).
It is believed to play a role in the function of the beta form of
platelet-derived growth factor receptor (PDGF-
R) with which it
interacts and participates in trimeric complexes with the E5 protein of
papillomaviruses (30). Deletion of the fourth transmembrane helix of
16K leads to reduced interactions with E5, the PDGF-
R, and
1 integrin (31, 24), and this truncated protein induces
anchorage-independent growth in 3T3 cells and enhances their growth as
tumors in nude mice (31). Even less is known about how 16K might
regulate
1 integrin functions. A role for 16K was
suggested by experiments showing that fibronectin induces a
redistribution of 16K-containing vesicles into proximity of the points
of contact between the cell and the extracellular matrix
(24).
R, the EGF-R, and
1 integrin pass through the ER
and Golgi, we conducted a study to assess whether 16K regulates receptor processing. Using lectins specific for different processing intermediates, we found that 16K inhibits the addition of
1,6-branched oligosaccharides to both
1 integrin and
the EGF-R. This result correlated with a loss of invasive growth. Each
individual transmembrane helix of 16K was expressed, and both the
second and fourth helices were able to inhibit
1,6 branching. This
inhibition occurred independently of direct binding to the receptors.
These and other data highlight a critical role for the
1
integrin transmembrane domain in the glycosylation of the protein and
reveal that 16K can regulate processing events that are implicated in cancer.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-minimum Eagle's medium in
10% fetal bovine serum at 37 °C in 5% CO2. All transfections were done using a standard calcium phosphate procedure. Unless otherwise described, HEK293 cells were incubated with
precipitate for 3 h, and lysates were made after 24 h of
expression. The HSV and T7 antibodies were obtained from Novagen, and
the anti-PDGF-
R was from Santa Cruz Biotechnology Inc. Alexa
488-cojugated goat anti-mouse was obtained from Molecular Probes, Inc.
Agarose-conjugated Phaseolus vulgaris leucoagglutinin
(L-PHA) and concanavalin A (ConA) and alkaline phosphatase-conjugated
rabbit anti-mouse IgG were purchased from Sigma. Alkaline
phospatase-conjugated goat anti-rabbit was from Chemicon.
1
Integrin--
Oligos encoding the 22 amino acid rat
1
integrin signal sequence (32) followed by the 11 amino acid T7 epitope
(33) were generated, annealed, and ligated into the BamHI
and EcoRI sites of pXJ41 to make XJ41-T7. These oligos also
added an XbaI site upstream of the BamHI site.
The assembled full-length bovine
1 integrin cDNA
(34) was inserted into this vector by directionally cloning
PCR-amplified products using the upstream primer
5'-GCTCTAGAGAAAATAGATGTTTG-3' and downstream primer
5'-CCGCTCGAGTCACTCATACTTCGGATT-3' into the XbaI and
XhoI sites of XJ41-T7 (pXJ41-T7-
1). The
mutation of Trp728 of
1 integrin to glycine
was done following the procedure of Kirsch and Joly (35) using the
upstream primer 5'-GCTGAGCATAAAGAATGT-3' and the downstream primer
5'-TAAAAGCTTCCCAATCAGCA-3'.
1 were resolved on
8% SDS-PAGE, transferred to nitrocellulose, blocked with 5% skim
milk, and probed with anti-T7 antibody. Detection was with nitro blue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate following
incubation with alkaline phosphatase-conjugated rabbit anti-mouse IgG.
Alternatively, lysates were treated with endoglycosidase H (2 units) or
glycopeptidase F and incubated at 37 °C overnight in recommended
buffers by the manufacturer (Calbiochem). Agarose-conjugated L-PHA and
ConA were used to isolate
1,6-branched and high mannose forms of
1 integrin, respectively. Lysates made from cells
co-transfected with HSV-tagged 16K were treated with anti-HSV antibody
and agarose-conjugated protein A, and recovered complexes were analyzed
by Western blot as described above. For experiments in which 16K was
co-transfected with
1 integrin or the EGF-R, total
amounts of DNA were made equal by the addition of parental pXJ41 vector.
-minimum Eagle's medium without serum. 2 × 104 HEK293 cells transiently transfected with 16K were
added to the top chamber and were allowed to penetrate the matrix for
22 h at 37 °C. The chambers were then washed three times with
PBS, and any remaining cells were removed from the top surface using a
cotton swab. Cells that had penetrated the membrane and reached the
lower surface were detected by Giemsa staining and counted. Control
cells transfected with the empty pXJ41 vector (mock transfected) were
able to invade all matrices tested.
1 integrin or co-transfected with 16K
were split 12 h following transfection. After 24 h, cells
were preincubated for 45 min in methionine-free Dulbecco's modified
Eagle's medium containing 2% fetal bovine serum and 2 mM
glutamine, washed twice with PBS, and then incubated in fresh methionine-free medium containing 2% fetal bovine serum, 2 mM glutamine, and 0.3 mCi/ml [35S]methionine
for 5 min at 37 °C. Cells were washed twice with PBS and either
lysed immediately in RIPA buffer or incubated in fresh Dulbecco's
modified Eagle's medium with excess methionine and 10% fetal bovine
serum for 10 or 20 min or 1, 2, 6, or 18 h, respectively,
followed by RIPA buffer lysis. Immunoprecipitations using anti-T7
antibody were recovered with protein A-Sepharose and resolved on 8%
SDS-polyacrylamide gels, which were then subjected to fluorography
(Amplify, Amersham Biosciences, Inc.), dried, and exposed to
film. Nontransfected HEK293 cells labeled for 4 h and treated with
anti-T7 antibody were used as a negative control.
1 integrin or with W728G mutant-tagged integrin were
fixed in 2% formaldehyde and transferred to a microfuge tube. Cells
were washed three times in PBS and recovered by low speed
microcentrifugation. Cells were then incubated with anti-HSV antibody
for 1 h at 4 °C, washed, and incubated with
Alexa-488-conjugated secondary antibody for 30 min at 4 °C.
Cells were washed three times with PBS and immediately analyzed using a
Coulter Elite flow cytometer.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1
Integrin--
16K and
1 integrin were tagged with HSV
and T7 epitopes, respectively, to permit specific detection following
transfection into HEK293 cells. ConA was used to detect molecules with
terminal mannose residues that are found predominantly in the ER, and
the lectin L-PHA was used to detect the
1,6-branched GlcNAc residues added by GlcNAc-TV. The T7 epitope-tagged
1 integrin
produced three main products (Fig. 1,
lane 1) that were identical in size to endogenous forms of
1 integrin (data not shown). The middle band
(~120-125 kDa) was reactive with ConA (lane 3) and
sensitive to endoH glycosidase (lane 5), identifying it as
the high mannose form present in the ER. Its size was reduced to that
of the ~110-115 kDa lower form by both endoH and glycopeptidase F
(lane 4). The lower form did not react with either ConA or
L-PHA, identifying it as unglycosylated core protein. The upper form
(~125-135 kDa) contained L-PHA-reactive molecules (lane
2), identifying it as the most mature product. Treatment with
brefeldin A, which blocks the transport from the ER to the Golgi,
inhibited the appearance of only the uppermost band, confirming that
the intermediate and low molecular weight forms were ER intermediates
(data not shown).

View larger version (28K):
[in a new window]
Fig. 1.
16K inhibits
1,6
branching of
1 integrin in HEK293
cells. A, lysates made from HEK293 cells transfected
with T7-tagged
1 integrin (lane 1) were
treated with agarose-conjugated L-PHA (lane 2),
agarose-conjugated ConA (lane 3), glycopeptidase F
(lane 4), or endoglycosidase H (lane 5) and
analyzed by Western blot analysis using anti-T7 antibody. Three forms
of T7-tagged
1 (~110, 125, and 135 kDa) were seen
(arrows). The interaction of 16K with
1
integrin was confirmed by analysis of lysates made from cells
co-transfected with T7-tagged
1 integrin and with
HSV-tagged 16K. Complexes were retrieved by immunoprecipitating with
anti-HSV antibody (lane 6) followed by agarose-conjugated
protein A. Lysates of cells transfected with T7-tagged
1
integrin immunoprecipitated with anti-HSV served as a negative control
(lane 7). B-E, HEK293 cells were co-transfected
with a constant amount of
1-T7 integrin and increasing
amounts (in µg) of HSV-tagged 16K. Proteins with
1,6-linked
oligosaccharides were isolated using agarose-conjugated L-PHA and
identified by probing with anti-T7 antibody (panel C).
Aliquots of lysates probed with anti-T7 (panel B) showed
that overall levels of
1 integrin were similar in all
samples, and anti-HSV antibody verified that 16K was expressed
incrementally (panel D). Increasing amounts of 16K resulted
in the reduction of the largest L-PHA-reactive form of
1
integrin (see arrow in panel B, lanes
2-6, and panel C, lanes 2-6) but did not
alter the expression of the PDGF-
R (panel E).
1 integrin in rat L6 myoblasts (24) was confirmed in
HEK293 cells by co-immunoprecipitation experiments using the
epitope-tagged proteins. Lysates from cells co-transfected with
T7-tagged
1 integrin and HSV-tagged 16K were
immunoprecipitated with anti-HSV antibody, and complexes were analyzed
by Western blots using anti-T7 antibody. The ~110 kDa core protein
was predominantly found in association with
1 integrin
(lane 6). Immunoprecipitations using anti-HSV from lysates
of cells transfected only with T7-tagged
1 integrin
served as a negative control (lane 7).
1,6 Branching of
1
Integrin--
We next assessed whether the repertoire of
1 integrin forms was dependent on the levels of 16K in
the cell (Fig. 1, B-E). Increasing amounts of the vector
encoding HSV-tagged 16K were co-transfected with a constant amount of
T7-tagged
1 integrin. As more 16K was made (Fig.
1D), the largest form of the integrin disappeared (Fig.
1B). This corresponded with a loss of L-PHA-reactive
1 molecules (Fig. 1C). There was not a
simultaneous build-up of ER-resident forms of the integrin, suggesting
that the decrease was because of an alteration in
1
integrin processing rather than retention of the integrin in the
ER. Western blot analysis of the same lysates for endogenous
PDGF-
R (Fig. 1E) showed that 16K does not affect
overall expression levels of other glycosylated cell surface receptors.
1,6 Branching by 16K Correlates with a Loss of
Migratory Abilities of HEK293 Cells--
In transwell invasion assays
(Fig. 2), the expression of 16K abrogated
migration through fibronectin and laminin (LN) matrices, demonstrating
a correlation between the loss of
1,6 branching and the invasive
abilities of cells. HEK293 cells transiently transfected with 16K were
split, and aliquots were plated on plastic (Fig. 2, A and
D), fibronectin (B and E), or LN
(C and F). Cells expressing 16K, identified by
immunofluorescence using anti-HSV antibody, were abundant on plastic
but nearly absent from the population that attached to fibronectin or
LN. This finding suggests that the inhibition of migration results from
an inhibition of attachment.

View larger version (57K):
[in a new window]
Fig. 2.
16K inhibits cell invasion and adhesion to
the integrin ligands laminin and fibronectin. HEK293 cells
transfected with 16K were examined for their ability to penetrate a
Costar transwell apparatus coated with 10 µg of laminin
(LN) or fibronectin (FN). Control cells
transfected with empty pXJ41 vector (mock transfected) were able to
invade all matrices tested, and this ability was lost upon the
expression of 16K. HEK293 cells transfected with HSV-tagged 16K were
split and plated overnight on plastic (A and D),
fibronectin (B and E), and laminin (C
and F). A-C show phase-contrast views of the
cells, whereas D-F show immunofluorescence with anti-HSV
followed by Alexa 488-conjugated secondary antibody. Cells expressing
16K were able to bind to tissue culture plastic but lost the ability to
attach to either laminin or fibronectin. Only the cells that were
nontransfected or expressing low levels of 16K were able to attach.
Scale bar = 250 µM.
1 Integrin Processing Is
Independent of V-ATPase Activity--
One possible explanation for the
effect of 16K on glycosylation is that GlcNAc-TV activity is highly
sensitive to the pH of the Golgi, and that by overexpressing 16K, the
activity of the V-ATPase is altered. If glycosylation was in fact
sensitive to pH, it would be predicted that a major disruption of
V-ATPase function would lead to altered processing.
Dicyclohexylcarbodiimide (DCCD) is a potent inhibitor of V-ATPase (39),
and it was used to treat cells that had been transfected with T7-tagged
1 integrin. After 2 h in DCCD, no changes in the
forms of integrin or in the amount of L-PHA-reactive molecules were
seen (Fig. 3A). Acridine orange was used to confirm that the DCCD had dramatically inhibited acidification of cellular compartments (Fig. 3B).
Pulse-chase labeling of transfected cells demonstrated that within
1 h newly synthesized
1 integrin polypeptides are
processed into all three prominent molecular mass forms (Fig.
3C). Therefore, we concluded that the lack of any effect on
glycosylation of a 2-h treatment with DCCD was strong evidence that 16K
is not altering glycosylation by altering V-ATPase activity. The
pulse-chase experiments also showed that over an 18-h period the
1,6-branched form of
1 integrin is never present
when16K is expressed.

View larger version (34K):
[in a new window]
Fig. 3.
Inhibition of V-ATPase activity does not
affect
1,6 branching of
1 integrin. A,
treatment of HEK293 cells transfected with
1 integrin
(lanes 2, 3, 5, and 6) with
the V-ATPase inhibitor DCCD (lanes 3 and 6) did
not inhibit
1,6 branching as detected using agarose-conjugated L-PHA
followed by Western blot analysis with anti-T7 antibody (lanes
5 and 6). B, acridine orange staining showed
that the concentration of DCCD used in panel A reduced the
pH of organelles acidified by the V-ATPase. C, shown are
pulse-chase experiments in which HEK293 cells were transfected with
either
1 integrin alone (lanes 2-8) or
co-transfected with
1 integrin and 16K (lanes
9-15). Cells were pulsed with [35S]methionine for 5 min, and complexes were retrieved from lysates using anti-T7 antibody
and agarose-conjugated protein A at 2, 5, 10, and 20 min and 1, 6, and
18 h, respectively. The larger, L-PHA-reactive form of
1 integrin (arrow) was seen after 1 h
(lane 6) in cells transfected with
1 integrin
alone and was not detected when 16K was present. Scale
bar = 150 µM.
1 Integrin--
Although 16K is
primarily a V-ATPase component, its interaction with
1
integrin raised the possibility that it also functions as a shuttling
molecule that can direct the integrin to bypass GlcNAc-TV. There are
many ER/Golgi components implicated in the trafficking of molecules,
such as ERGIC-53, Rab6, the ADP-ribosylation factor family of
proteins, COP1, COP2, and SNARES (39-47). ERGIC-53, for example,
transports glycoproteins through compartments, presumably via direct
association with glycan intermediates (48). Because glycosylation
occurs sequentially through different compartments, we examined whether
the inhibitory effect of 16K on glycosylation of
1
integrin was dependent on their association. A series of HSV
epitope-tagged truncated 16K molecules (Fig.
4, upper panel) was made, and
their ability to bind
1 integrin in
co-immunoprecipitation experiments was compared with their ability to
promote the loss of
1,6 branching.

View larger version (28K):
[in a new window]
Fig. 4.
Inhibition of glycosylation does not depend
on a direct association between
1
integrin and 16K. Upper panel, 16K derivatives
comprised of specific hydrophobic helices were generated with
carboxyl-terminal HSV tags. Lower panel, HEK293 cells were
transfected with
1-T7 only (lane 1) or
co-transfected with
1-T7 and the 16K derivative
(lanes 2-10). Integrin expression was assessed by
Western blot analysis of RIPA lysates probed with anti-T7 antibody
(panel A), and glycosylation by GlcNAc-TV was assessed by
incubating extracts with agarose-conjugated L-PHA and analyzing
recovered proteins with anti-T7 antibody (panel B). Proteins
interacting with 16K or 16K mutants were isolated by
immunoprecipitation using anti-HSV antibody followed by
agarose-conjugated protein A, and recovery of
1-T7
integrin was monitored by Western blot analysis using anti-T7 antibody
(panel C).
1 integrin required the
region of the protein spanning helices 2-4 with helix 4 contributing the most to the interaction (Fig. 4C, lanes
8-10). This finding confirmed our earlier results using the yeast
two-hybrid assay and direct protein interaction studies, showing the
importance of helix 4 for the interaction (24). Although no individual helices formed stable interactions with
1 integrin,
helices 2 and 4 suppressed
1,6 branching as effectively as
full-length 16K (Fig. 4, A and B, lanes
3, 5, and 10), whereas helices 1 and 3 had
only a small effect (lanes 2 and 4). Helix 2 was
less active when present with helix 1 (lane 6), but
otherwise all variants tested that had either helix 2 or 4 could
suppress L-PHA reactivity (lanes 7-9). Helices 1 and 3 resulted in less of the ConA-reactive smaller form of
1
integrin. These data indicate that specific regions of 16K can affect
processing independently of direct association with
1
integrin. 16K is believed to have arisen from a duplication of an 8-kDa
progenitor protein with two hydrophobic helices (49-51), which may
underlie the similarity in functions of alternate helices with respect
to the glycosylation of
1 integrin.
1
Integrin Are Required for Control of
1,6 Branching--
These
results, which show that membrane-spanning hydrophobic fragments of 16K
could influence
1 integrin processing, led us to predict
that the transmembrane domain of
1 integrin played a
role in processing. We created mutations spanning the integrin transmembrane domain, expressed them as T7-tagged
proteins,2 and assessed their
effect on glycosylation. Whereas most mutations had little effect, the
conversion of Trp728, which is buried in the membrane near
the cytoplasmic surface (Fig.
5A), to glycine caused
processing to become strikingly similar to that seen when 16K was
co-expressed with wild type
1 integrin. That is, there
was a significant reduction of
1,6 branching of this mutant
(lanes 1-6). At the same time, the core protein form of
this mutant retained its ability to interact with 16K (lanes 7-10). The mutation of Trp728 to glycine does not
affect the ability of the integrin to get to the cell surface (Fig.
5B) nor its ability to bind to the integrin matrices
fibronectin, laminin, or vitronectin (data not shown) and,
therefore, is probably not altering the conformation of the integrin.
These data further demonstrate that glycosylation can be orchestrated
from within the membrane and in addition suggest that 16K might target
an intermediary factor whose interaction with
1 integrin
is abrogated by this tryptophan mutation.

View larger version (45K):
[in a new window]
Fig. 5.
The transmembrane domain of
1 integrin contributes to
1,6 branching. A, HEK293 cells were
transfected with wild type T7-tagged
1 integrin
(lanes 2, 3, 5, 6,
8, and 10) or the W728G transmembrane mutant
(lanes 1, 4, 7, and 9)
1 integrin. Four of the wild type T7-
1
samples (lanes 2, 5, 8, and
10) and two of the W728G mutant samples (lanes 7 and 9) had HSV-16K included in the transfection. Western
blots of RIPA lysates probed with anti-T7 as shown in lanes
1-3 and lanes 9 and 10 confirm that the
mutant and wild type are expressed at similar levels.
1,6-Branched
proteins, recovered using L-PHA-conjugated agarose, are reduced
similarly by co-transfection with 16K or by the mutant (lanes
4-6). Immunoprecipitations with anti-HSV antibody from
co-transfected cells (lanes 7 and 8) show that
the W728G mutation does not interfere with binding of the core integrin
protein to16K. B, flow cytometry experiments revealed that
the integrin mutant W728G is expressed on the surface of the cell at
levels comparable with those of the wild type-tagged
1
integrin.
1,6-branched oligosaccharides, and
it too was T7 epitope-tagged and expressed in HEK293 cells along with
T7-tagged
1 integrin and increasing amounts of
HSV-tagged 16K (Fig. 6).
1,6-Branched
proteins were isolated using L-PHA-conjugated agarose and analyzed by
Western blots probed with anti-T7 antibody. As with
1
integrin, the L-PHA-reactive form of the EGF-R was suppressed by 16K
(lanes 1-4). Co-immunoprecipitation experiments (data not
shown) failed to detect any interaction between 16K and the EGF-R,
again confirming that modulation of glycosylation by 16K occurs without
direct interaction with the glycosylation substrate.

View larger version (39K):
[in a new window]
Fig. 6.
16K inhibits
1,6
branching of the EGF-R. HEK293 cells were co-transfected
with T7-tagged
1 integrin and the EGF-R. Lanes
1-4 contain equal amounts of T7-tagged EGF-R and
1
integrin with increasing amounts of HSV-tagged 16K. Lanes 5 and 6 show lysates transfected with only
1
integrin or EGF-R, respectively. A, Western blot analysis of
RIPA lysates treated with anti-T7 antibody. B, increasing
amounts of 16K suppress
1,6 branching of both
1
integrin (lower band) and the EGF-R (upper band),
as detected using L-PHA-conjugated agarose and Western blot analysis
with anti-T7 antibody.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1
integrin processing. Furthermore, to add to the complexity of these
data, 16K can form a stable complex with
1 integrin, but
the effect of 16K on glycosylation is not dependent upon this interaction.
1 integrin through the Golgi, and 16K overexpression could cause the integrin to be diverted prematurely to proteasomes or
the cell surface without full processing occurring. On the other hand,
16K may somehow regulate GlcNAc-TV or the mechanisms, which determine
how the transferase finds its targets.
-helical subdomain of 16K, which has
no ability to bind
1 integrin, can regulate processing
and that the EGF-R is also affected even though it does not bind to 16K
makes a cargo receptor role for 16K seem unlikely. ER to Golgi cargo
receptors, such as ERGIC-53, are also structurally unrelated to 16K,
functioning as mannose-specific lectins (40). In addition, the overall
levels of
1 integrin or the EGF-R are not significantly reduced by the addition of 16K, indicating that proteolysis is not
being enhanced.
1 integrin was found in our study to play a key role in
the ability of that molecule to become
1,6-branched. Notably, the
mutation of Trp728 resulted in levels of
1,6 branching
that were identical to those seen when 16K was overexpressed. The most
direct interpretation is that Trp728 is required for a
direct interaction between GlcNAc-TV and
1 integrin or
for the interaction with another molecule(s) that is needed for
GlcNAc-TV to have access to
1 integrin. Do et
al. (56) showed that
1,6 branching is in fact dependent upon
GlcNAc-TV having access to suitable oligosaccharide acceptors.
Increasing amounts of 16K could compete for GlcNAc-TV or for this other
molecule, thereby altering glycosylation of
1 integrin.
It is predicted that other
1,6-branched receptors such as the EGF-R
also participate in similar complexes with which 16K can
compete. Clearly, it will now be necessary to search for other
putative transmembrane partners of
1 integrin, the
EGF-R, GlcNAc-TV, and 16K. We recently identified in a yeast two-hybrid
screen two additional uncharacterized binding partners for
1 integrin (24).
1,6 branching in response to increasing amounts of
16K may also be the result of the inhibition of GlcNAc-TV expression.
The GlcNAc-TV gene is itself sensitive to signaling pathways
with ets-dependent activation by src kinase and
by her-2/neu stimulation of the Ras-Raf signaling pathway
playing a role (57, 58). In addition, the processing of
1 integrin can be accelerated by TGF-
1
through the stimulation of Ras (59), suggesting that any effects of 16K
on signaling pathways using Ras could affect glycosylation. It is also
a reasonable expectation that the involvement of 16K in cell surface
receptor glycosylation will in turn perturb gene expression pathways by
altering receptor function. In support of this finding, it has been
suggested that a role of N-linked glycosylation is to
prevent surface receptors from dimerizing in the absence of an
appropriate ligand (60). Additionally, the inhibition of
1,6
branching in GlcNAc-TV knockout mice enhances the clustering of T cells
and lowers T cell activation (61).
1 integrin or the EGF-R. In our experiments, we
observed a >90% loss of
1,6 branching of these targets and a
concurrent dramatic reduction in migration through extracellular matrix
components. 16K may provide unique opportunities for the intervention
in
1,6 branching and reduction of invasive cell growth.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Zhao Lu for cloning the human 16K cDNA, Dr. M.A. Billeter for the gift of the HEK293-T7 cell line, and Jan Brazolot for technical assistance with flow cytometry.
| |
FOOTNOTES |
|---|
* This work was supported by the Natural Sciences and Engineering Research Council of Canada.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence may be addressed. Tel.: 519-824-4120, Ext.
4841; Fax: 519-837-2075; E-mail: mskinner@uoguelph.ca.
§ To whom correspondence may be addressed. Tel.: 519-824-4120, Ext. 2486; Fax: 519-837-2075; E-mail: wildeman@uoguelph.ca.
Published, JBC Papers in Press, October 16, 2001, DOI 10.1074/jbc.M103569200
2 M. A. Skinner and A. G. Wildeman, manuscript in preparation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
ER, endoplasmic reticulum;
GlcNAc TI-V, N-acetylglucosaminyltransferases I-V;
EGF-R, epidermal
growth factor receptor;
16K, 16-kDa transmembrane subunit;
V-ATPase, vacuolar H+-ATPase;
PDGF-
R, platelet-derived growth
factor receptor;
HEK, human embryonal kidney;
HSV, herpes simplex
virus;
L-PHA, P. vulgaris leucoagglutinin;
ConA, concanavalin A;
SNARES, soluble N-ethylmaleimide-sensitive
fusions attachment protein receptor;
RIPA, radioimmune precipitation
buffer;
PBS, phosphate-buffered saline;
DCCD, dicyclohexylcarbodiimide.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Demetriou, M.,
Nabi, I. R.,
Coppolino, M.,
Dedhar, S.,
and Dennis, J. W.
(1995)
J. Cell Biol.
130,
383-392 |
| 2. |
Seberger, P. J.,
and Chaney, W. G.
(1999)
Glycobiology
9,
235-241 |
| 3. | Granovsky, M., Fata, J., Pawling, J., Muller, W. J., Khokha, R., and Dennis, J. W. (2000) Nat. Med. 6, 306-312[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Dennis, J. W.,
Laferté, S.,
Waghorne, C.,
Breitman, M. L.,
and Kerbel, R. S.
(1987)
Science
236,
582-585 |
| 5. | Dennis, J. W., Granovsky, M., and Warren, C. E. (1999) Biochim. Biophys. Acta 1473, 21-34[Medline] [Order article via Infotrieve] |
| 6. |
Seelentag, W. K. F.,
Li, W.-P.,
Schmitz, S.-F. H.,
Metzger, U.,
Aeberhard, P.,
Heitz, P. U.,
and Roth, J.
(1998)
Cancer Res.
58,
5559-5564 |
| 7. |
Murata, K.,
Miyoshi, E.,
Kameyama, M.,
Ishikawa, O.,
Kabuto, T.,
Sasaki, Y.,
Hiratsuka, M.,
Ohigashi, H.,
Ishiguro, S.,
Ito, S.,
Honda, H.,
Takemura, F.,
Taniguchi, N.,
and Imaoka, S.
(2000)
Clin. Cancer Res.
6,
1772-1777 |
| 8. | Shao, D. M., Wang, Q. H., Chen, C., Shen, Z. H., Yao, M., Zhou, X. D., Tang, Z. Y., and Gu, J. X. (1999) J. Exp. Clin. Cancer Res. 18, 331-335[Medline] [Order article via Infotrieve] |
| 9. |
Fernandes, B.,
Sagman, U.,
Auger, M.,
Demetriou, M.,
and Dennis, J. W.
(1991)
Cancer Res.
51,
718-723 |
| 10. |
Jasiulionis, M. G.,
Chammas, R.,
Ventura, A. M.,
Travassos, L. R.,
and Brentani, R. R.
(1996)
Cancer Res.
56,
1682-1689 |
| 11. | Braut-Boucher, F., Font, J., Pichon, J., Paulin, Y., Boukhelifa, M., Aubery, M., and Derappe, C. (1998) Leuk. Res. 22, 947-952[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Litynska, A., Przybylo, M., Ksiazek, D., and Laidler, P. (2000) Acta Biochim. Pol. 47, 427-434[Medline] [Order article via Infotrieve] |
| 13. | Smith, K. D., Davies, M. J., Bailey, D., Renouf, D. V., and Hounsell, E. F. (1996) Growth Factors 13, 121-132[Medline] [Order article via Infotrieve] |
| 14. | Arao, S., Masumoto, A., and Otsuki, M. (2000) Pancreas 20, 129-137[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Nishimura, S., Chung, Y. S., Yashiro, M., Inoue, T., and Sowa, M. (1996) Br. J. Cancer 74, 1406-1412[Medline] [Order article via Infotrieve] |
| 16. | Stroeken, P. J., van Ritjthoven, E. A., Boer, E., Geerts, D., and Roos, E. (2000) Oncogene 19, 1232-1238[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Seftor, R. E., Seftor, E. A., and Hendrix, M. J. (1999) Cancer Metastasis Rev. 18, 359-375[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Fishman, D. A., Kearns, A., Chilukuri, K., Bafetti, L. M., O'Toole, E. A., Georgacopoulos, J., Ravosa, M. J., and Stack, M. S. (1998) Invasion Metastasis 18, 15-26[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Park, R. H., and Yun, I. (1996) Cancer Lett. 106, 227-233[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Bartlett, J. M., Langdon, S. P., Simpson, B. J., Stewart, M., Katsaros, D., Sismondi, P., Love, S., Scott, W. N., Williams, A. R., Lessells, A. M., Macleod, K. G., Smyth, J. F., and Miller, W. R. (1996) Br. J. Cancer 73, 301-306[Medline] [Order article via Infotrieve] |
| 21. |
Kersemaekers, A. M.,
Fleuren, G. J.,
Kenter, G. G.,
Van den Broek, L. J.,
Uljee, S. M.,
Hermans, J.,
and Van de Vijver, M. J.
(1999)
Clin. Cancer Res.
5,
577-586 |
| 22. | Kim, H., and Muller, W. J. (1999) Exp. Cell Res. 253, 78-87[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Huang, S. M., and Harari, P. M. (1999) Invest. New Drugs 17, 259-269[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Skinner, M. A.,
and Wildeman, A. G.
(1999)
J. Biol. Chem.
274,
23119-23127 |
| 25. |
Feng, Y.,
and Forgac, M.
(1992)
J. Biol. Chem.
267,
19769-19772 |
| 26. |
Nelson, N.
(1992)
J. Exp. Biol.
172,
149-153 |
| 27. | Finbow, M. E., Harrison, M., and Jones, P. (1995) Bioessays 17, 247-255[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Brochier, G., and Morel, N. (1993) Neurochem. Int. 23, 525-539[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Finbow, M. E., Goodwin, S. F., Meagher, L., Lane, N. J., Keen, J., Findlay, J. B., and Kaiser, K. (1994) J. Cell Sci. 107, 1817-1824[Abstract] |
| 30. | Goldstein, D. J., Andresson, T., Sparkowski, J. J., and Schlegel, R. (1992) EMBO J. 11, 4851-4859[Medline] [Order article via Infotrieve] |
| 31. |
Andresson, T.,
Sparkowski, J.,
Goldstein, D. J.,
and Schlegel, R.
(1995)
J. Biol. Chem.
270,
6830-6837 |
| 32. | Malek-Hedayat, S., and Rome, L. H. (1995) Gene (Amst.) 158, 287-290[CrossRef][Medline] [Order article via Infotrieve] |
| 33. |
Tsai, D. E.,
Kenan, D. J.,
and Keene, J. D.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
8864-8868 |
| 34. | MacLaren, L. A., and Wildeman, A. G. (1995) Biol. Reprod. 53, 153-165[Abstract] |
| 35. |
Kirsch, R. D.,
and Joly, E.
(1998)
Nucleic Acids Res.
26,
1848-1850 |
| 36. | Zuzarte, P. C., Farrance, I. K., Simpson, P. C., and Wildeman, A. G. (2000) Biochim. Biophys. Acta 1517, 82-90[Medline] [Order article via Infotrieve] |
| 37. | Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., and Schlessinger, J. (1984) Nature 309, 418-425[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Albini, A., Aukerman, S. L., Ogle, R. C., Noonan, D. M., Fridman, R., Martin, G. R., and Fidler, I. J. (1989) Clin. Exp. Metastasis 7, 437-451[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Finbow, M. E., John, S., Kam, E., Apps, D. K., and Pitts, J. D. (1993) Exp. Cell Res. 207, 261-270[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Hauri, H. P., Kappeler, F., Andersson, H., and Appenzeller, C. (2000) J. Cell Sci. 113, 587-596[Abstract] |
| 41. | Bannykh, S. I., Nishimura, N., and Balch, W. E. (1998) Trends Cell Biol. 8, 21-25[CrossRef][Medline] [Order article via Infotrieve] |
| 42. | Barlowe, C., Orci, L, Yeung, T., Hosobuchi, M., Hamamoto, S., Salama, N., Rexach, M. F., Ravazzola, M., Amherdt, M., and Schekman, R. (1994) Cell 77, 895-907[CrossRef][Medline] [Order article via Infotrieve] |
| 43. | Martinez-Menàrguez, J. A., Geuze, H. J., Slot, J. W., and Klumperman, J. (1999) Cell 98, 81-90[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Rothman, J. E. (1994) Nature 372, 55-63[CrossRef][Medline] [Order article via Infotrieve] |
| 45. | Presley, J. F., Cole, N. B., Schroer, T. A., Hirschberg, K., Zaal, K. J., and Lippincott-Schwartz, J. (1997) Nature 389, 81-85[CrossRef][Medline] [Order article via Infotrieve] |
| 46. |
Ladinsky, M. S.,
Mastronarde, D. N.,
McIntosh, J. R.,
Howell, K. E.,
and Staehelin, L. A.
(1999)
J. Cell Biol.
144,
1135-1149 |
| 47. | Appenzeller, C., Andersson, H., Kappeler, F., and Hauri, H. P. (1999) Nat. Cell Biol. 1, 330-334[CrossRef][Medline] [Order article via Infotrieve] |
| 48. |
Moussalli, M.,
Pipe, S. W.,
Hauri, H. P.,
Nichols, W. C.,
Ginsburg, D.,
and Kaufman, R. J.
(1999)
J. Biol. Chem.
274,
32539-32542 |
| 49. | Finbow, M. E., and Harrison, M. A. (1997) Biochem. J. 324, 697-712 |
| 50. | Kibak, H., Taiz, L., Starke, T., Bernasconi, P., and Gogarten, J. P. (1992) J. Bioenerg. Biomembr. 24, 415-424[CrossRef][Medline] [Order article via Infotrieve] |
| 51. | Nelson, H., and Nelson, N. (1989) FEBS Lett. 247, 147-153[CrossRef][Medline] [Order article via Infotrieve] |
| 52. | Guo, H. B., Liu, F., Zhao, J. H., and Chen, H. L. (2000) J. Cell. Biochem. 79, 370-385[CrossRef][Medline] [Order article via Infotrieve] |
| 53. | Peters, C., Bayer, M. J., Bühler, S., Andersen, J. S., Mann, M., and Mayer, A. (2001) Nature 409, 581-588[CrossRef][Medline] [Order article via Infotrieve] |
| 54. |
Tachibana, I.,
Bodorova, J.,
Berditchevski, F.,
Zutter, M. M.,
and Hemler, M. E.
(1997)
J. Biol. Chem.
272,
29181-29191 |
| 55. |
Claas, C.,
Stipp, C. S.,
and Hemler, M. E.
(2001)
J. Biol. Chem.
276,
7974-7984 |
| 56. |
Do, K. Y.,
Fregien, N.,
Pierce, M.,
and Cummings, R. D.
(1994)
J. Biol. Chem.
269,
23456-23464 |
| 57. |
Buckhaults, P.,
Chen, L.,
Fregien, N.,
and Pierce, M.
(1997)
J. Biol. Chem.
272,
19575-19581 |
| 58. | Chen, L., Zhang, W., Fregien, N., and Pierce, M. (1998) Oncogene 17, 2087-2093[CrossRef][Medline] [Order article via Infotrieve] |
| 59. | Bellis, S. L., Newman, E., and Friedman, E. A. (1999) J. Cell. Physiol. 181, 33-44[CrossRef][Medline] [Order article via Infotrieve] |
| 60. |
Tsuda, T.,
Ikeda, T.,
and Taniguchi, N.
(2000)
J. Biol. Chem.
275,
21988-21994 |
| 61. | Demetriou, M., Granovsky, M., Quaggin, S., and Dennis, J. W. (2001) Nature 409, 733-739[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
I. Lee, M. A. Skinner, H.-b. Guo, A. Sujan, and M. Pierce Expression of the Vacuolar H+-ATPase 16-kDa Subunit Results in the Triton X-100-insoluble Aggregation of {beta}1 Integrin and Reduction of Its Cell Surface Expression J. Biol. Chem., December 17, 2004; 279(51): 53007 - 53014. [Abstract] [Full Text] [PDF] |
||||
![]() |
|